LGVN Share Price Performance
US$0.56
-1.21 (-68.47%)
94.7% undervalued intrinsic discount
US$10.45
Fair Value
Price US$0.56
AnalystHighTarget US$10.45
AnalystLowTarget US$3.00
AnalystConsensusTarget US$6.86
Fair ValueUS$10.45
Share Pricen/a
Longeveron Inc. Stock Price
- 3 Narratives written by author
- 1 Comments on narratives written by author
- 11 Fair Values set on narratives written by author
LGVN Community Narratives
AN
Fair Value US$10.45 94.7% undervalued intrinsic discount
HLHS Trials And Aging Demographics Will Expand Regenerative Markets
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value US$3 81.4% undervalued intrinsic discount
High Costs And HLHS Hurdles Will Crimp Prospects, Spark Renewal
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$6.86 91.9% undervalued intrinsic discount
FDA Alignment And HLHS Trial Will Enable Market Access
1users have liked this narrative
1users have commented on this narrative
7users have followed this narrative
HLHS Trials And Aging Demographics Will Expand Regenerative Markets
Key Takeaways Strong clinical and regulatory positioning in multiple rare diseases, combined with advantageous designations, bolsters expedited approvals, commercial potential, and recurring revenue streams. Leadership in next-generation regenerative therapies and scalable manufacturing supports long-term growth, pipeline expansion, and improving profitability amid increasing healthcare demand.Read more
12
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$10.45
94.7% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
146.1% p.a.
Profit Margin
14.17%
Future PE
63.94x
Price in 2028
US$17.22
FDA Alignment And HLHS Trial Will Enable Market Access
Key Takeaways Progress towards regulatory approval and commercialization for a lead therapy could significantly boost revenue and move the company closer to profitability. Expansion into new rare disease markets and innovative technologies supports long-term growth and reduces reliance on a single product.Read more
41
users have viewed this narrative1users have liked this narrative
1users have commented on this narrative
7users have followed this narrative
AN
US$6.86
91.9% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
190.06% p.a.
Profit Margin
16.06%
Future PE
22.62x
Price in 2028
US$11.31
High Costs And HLHS Hurdles Will Crimp Prospects, Spark Renewal
Key Takeaways Heavy dependence on successful clinical approvals and external funding exposes Longeveron to significant revenue and operational uncertainty. Rising expenses, limited cash runway, and uncertain commercialization prospects increase the risk of future dilution and financial instability.Read more
9
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$3
81.4% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
145.28% p.a.
Profit Margin
16.25%
Future PE
16.16x
Price in 2028
US$4.94
Trending Discussion
Recently Updated Narratives
AN
High Costs And HLHS Hurdles Will Crimp Prospects, Spark Renewal
Fair Value: US$3 81.4% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
HLHS Trials And Aging Demographics Will Expand Regenerative Markets
Fair Value: US$10.45 94.7% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
FDA Alignment And HLHS Trial Will Enable Market Access
Fair Value: US$6.86 91.9% undervalued intrinsic discount
7 followersusers have followed this narrative
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Longeveron Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -1.00
- 74.88%
- -1,485.11%
- 0%
About LGVN
- Founded
- 2014
- Employees
- 25
- CEO
- WebsiteView website
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 1 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer’s disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.
